Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor... | May 12, 2023

Related Keywords

United States ,American ,Darren Cline ,Christina Tartaglia ,Michaelw Kalb ,Adrian Adams ,Melyssa Weible ,Impel Pharmaceuticals Inc ,American Academy Of Neurology ,Astrazeneca ,Exchange Commission ,Cincor Pharma Inc ,Elixir Health Public Relations ,Nasdaq ,Impel Pharmaceuticals ,Company Developments ,Development Rd Expenses ,Net Product Revenue ,Host Investor Conference Call Today ,Chief Executive Officer ,Dihydroergotamine Mesylate ,Nasal Spray ,Eper Spray ,Annual Meeting ,Chief Financial Officer ,Executive Vice President ,Cincor Pharma ,First Quarter ,Product Revenue ,Cash Runway ,Pharmaceutical Executive Management ,Conference Registration ,Precision Olfactory Delivery ,Securities Litigation Reform Act ,Consolidated Statement ,Three Months Ended March ,Impel Pharmaceuticals Inc Stock Exchange ,News ,Information ,Press Release ,Chieved ,Etrx ,F ,Dover ,N ,1 ,Increase ,022 ,Rudhesa ,Pet ,Product ,Revenue ,023 ,Ncreased ,O ,Billion ,Campel ,Ost Impl Us45258k1097 ,